Monoclonal antibodies in immune and inflammatory diseases
- 1 December 2002
- journal article
- review article
- Published by Elsevier in Current Opinion in Biotechnology
- Vol. 13 (6) , 615-620
- https://doi.org/10.1016/s0958-1669(02)00355-5
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- Cytokines and anti-cytokine biologicals in autoimmunity: present and futureCytokine & Growth Factor Reviews, 2002
- Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open‐label studyRheumatology, 2002
- Development of anti-TNF therapy for rheumatoid arthritisNature Reviews Immunology, 2002
- Anti-TNFα Therapy of Rheumatoid Arthritis: What Have We Learned?Annual Review of Immunology, 2001
- Infliximab and Methotrexate in the Treatment of Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- THE THERAPEUTIC EFFECTS OF AN ENGINEERED HUMAN ANTI-TUMOUR NECROSIS FACTOR ALPHA ANTIBODY (CDP571) IN RHEUMATOID ARTHRITISRheumatology, 1995
- Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritisThe Lancet, 1994
- Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritisThe Lancet, 1994
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor αArthritis & Rheumatism, 1993